# Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

> **NCT01246076** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 24 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01246076
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-05
- **Final completion:** 2015-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246076, "Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01246076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*